Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Precipio Q3 2026 Results: Net Loss of $8K, Loss Narrows

Precipio, Inc. reported net sales of $21.1 million for the nine months ended September 30, 2026, a significant increase from $17.4 million in the prior year period. Despite the revenue growth, the company recorded a net loss of $1.67 million for the first nine months of 2026, compared to a net loss of $0.89 million in 2025, primarily driven by higher operating expenses.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue7.46.9
Gross profit3.43.0
Profit before tax-0.0-0.1
Net income-0.0-0.1
EPS (diluted, $ a share)—$-0.05

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+7.3%
Gross margin45.7%
Operating margin0.0%
Source

10-Q filed with the SEC, NASDAQ: PRPO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Precipio, Inc.: key numbers

Share price
$19.96Close, Nov 16
Market cap
$35.8M
Shares outstanding
1.79MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Precipio, Inc.

All →
4:16 PM ET 8-K
Financial Results

Precipio Financial Results

Precipio reported record quarterly revenue of $7.3 million for Q3 2026, driven by growth in both its pathology and product segments. The company achieved positive Adjusted EBITDA of $0.4 million and generated $0.6 million in cash flow from operations, ending the period with a cash balance of $3.5 million.

Term
Q3 2026

“In the third quarter we continued to strengthen our financial position, delivering record revenue while maintaining positive Adjusted EBITDA and generating cash from operations.”

Ilan Danieli, CEO of Precipio

“Our pathology business continues to provide a strong operational and financial foundation for growth, while also serving as the clinical development and validation platform for our proprietary diagnostic products.”

Ilan Danieli, CEO of Precipio

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.